1160931-80-5

Basic information

• Product Name: 1-(4-methoxybenzyl)-3-cyclopropyl-1H-pyrazol-5-amine
• Synonyms: 1-(4-methoxybenzyl)-3-cyclopropyl-1H-pyrazol-5-amine
• CAS NO: 1160931-80-5
• Molecular Weight: 243.308
• Mol File: 1160931-80-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1-(4-methoxybenzyl)-3-cyclopropyl-1H-pyrazol-5-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-methoxybenzyl)-3-cyclopropyl-1H-pyrazol-5-amine(1160931-80-5)
• EPA Substance Registry System: 1-(4-methoxybenzyl)-3-cyclopropyl-1H-pyrazol-5-amine(1160931-80-5)

Safety Data

• Hazardous Substances Data: 1160931-80-5(Hazardous Substances Data)

Upstream product

• 2011-48-5 1-(4-methoxybenzyl)hydrazine hydrochloride 
• 118431-88-2 3-cyclopropyl-3-oxo-propionitrile 
• 175137-46-9 5-cyclopropyl-2H-pyrazol-3-ylamine 
• 824-94-2 p-methoxybenzyl chloride 

Downstream Products

• 1160931-82-7 N-(1-(4-methoxybenzyl)-3-cyclopropyl-1H-pyrazol-5-yl)-2-(5-((5-(4-chlorophenyl)furan-2-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)acetamide 

Relevant articles and documents

HSP90 INHIBITORS AND USES THEREOF

Herein is described the design and synthesis of resorcylate aminopyrazole compounds. These compounds show broad, potent and fungal-selective Hsp90 inhibitory activity. These compounds also find use in treating Hsp90 related deseases.

PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS KINASE JAK-2 INHIBITORS

A compound of the general formula (I), useful for treating myeloproliferative, cancer,or inflammatory diseases, wherein Q represents a six-membered heteroaromatic ring containing 2 N atoms and R1 is hydrogen atom,or Q represents a five-membered heteroaromatic ring containing 1 or 2 heteroatoms selected from the group consisting of N and S,one substituent R1 is attached at C or N atom of said Q ringand R1 is selected from the group consisting of C1-C4-alkyl and C3-C4-cycloalkyl;R2 represents-NR7aR7bor-CH2-NR8aR8b;R3 represents C1-C4-alkyl;R4 represents phenylora 5-or 6-membered heteroarylcontaining 1 or 2 heteroatoms selected from the group consisting of N and S, and R4 is unsubstituted or substituted with 1 or 2 substituents selected from the group consisting of halogen, trifluoromethyl,hydroxyl and C1-C4-alkoxyl;R5 and R6 independently represent hydrogenatom or C1-C4-alkyl,and at least one of R5 and R6 represents hydrogen atom;and other substituents are as defined in the specification; and pharmaceutically acceptable salts thereof.